Go Pro
→ 7 Bankers Met in Secret (Now We Pay for It) (From Decentralized Masters) (Ad)tc pixel Free MRKR Stock Alerts

Marker Therapeutics (MRKR) Competitors

Marker Therapeutics logo
$1.25 +0.03 (+2.46%)
As of 02:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

MRKR vs. THAR, GANX, FRMM, SPRO, and XBIT

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include Tharimmune (THAR), Gain Therapeutics (GANX), Forum Markets (FRMM), Spero Therapeutics (SPRO), and XBiotech (XBIT).

How does Marker Therapeutics compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Marker Therapeutics (NASDAQ:MRKR) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 689.89%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Tharimmune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tharimmune
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Tharimmune has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Tharimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
TharimmuneN/A -588.45% -264.41%
Marker Therapeutics -343.03%-73.29%-59.70%

Tharimmune has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company Overall Sentiment
Tharimmune Neutral
Marker Therapeutics Neutral

Marker Therapeutics has higher revenue and earnings than Tharimmune. Marker Therapeutics is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TharimmuneN/AN/A-$12.20M-$3.99N/A
Marker Therapeutics$3.55M5.94-$12.16M-$0.61N/A

Summary

Marker Therapeutics beats Tharimmune on 10 of the 13 factors compared between the two stocks.

How does Marker Therapeutics compare to Gain Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Marker Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 689.89%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 329.80%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Gain Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Marker Therapeutics has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.55M5.94-$12.16M-$0.61N/A
Gain Therapeutics$50K1,488.49-$20.16M-$0.58N/A

In the previous week, Gain Therapeutics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Gain Therapeutics and 0 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled Gain Therapeutics'average media sentiment score.

Company Overall Sentiment
Marker Therapeutics Neutral
Gain Therapeutics Neutral

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Marker Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker Therapeutics-343.03% -73.29% -59.70%
Gain Therapeutics N/A -201.44%-136.24%

Summary

Marker Therapeutics beats Gain Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Forum Markets?

Marker Therapeutics (NASDAQ:MRKR) and Forum Markets (NASDAQ:FRMM) are related small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Marker Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

Marker Therapeutics has higher earnings, but lower revenue than Forum Markets. Marker Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.55M5.94-$12.16M-$0.61N/A
Forum Markets$6.55M11.39-$450.52M-$36.07N/A

In the previous week, Forum Markets had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Forum Markets and 0 mentions for Marker Therapeutics. Forum Markets' average media sentiment score of 0.34 beat Marker Therapeutics' score of 0.00 indicating that Forum Markets is being referred to more favorably in the news media.

Company Overall Sentiment
Marker Therapeutics Neutral
Forum Markets Neutral

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 689.89%. Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 79.53%. Given Marker Therapeutics' higher possible upside, equities research analysts plainly believe Marker Therapeutics is more favorable than Forum Markets.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Forum Markets
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 25.2% of Forum Markets shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Forum Markets has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Forum Markets' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker Therapeutics-343.03% -73.29% -59.70%
Forum Markets N/A -242.09%-135.46%

Summary

Forum Markets beats Marker Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Marker Therapeutics compare to Spero Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Spero Therapeutics had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled Spero Therapeutics'average media sentiment score.

Company Overall Sentiment
Marker Therapeutics Neutral
Spero Therapeutics Neutral

Marker Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 689.89%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Marker Therapeutics is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Spero Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Spero Therapeutics has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.55M5.94-$12.16M-$0.61N/A
Spero Therapeutics$66.80M1.04$8.57M$0.245.02

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spero Therapeutics has a net margin of 24.90% compared to Marker Therapeutics' net margin of -343.03%. Spero Therapeutics' return on equity of 35.58% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker Therapeutics-343.03% -73.29% -59.70%
Spero Therapeutics 24.90%35.58%24.95%

Marker Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Spero Therapeutics beats Marker Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to XBiotech?

Marker Therapeutics (NASDAQ:MRKR) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 689.89%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than XBiotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marker Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Marker Therapeutics has higher revenue and earnings than XBiotech. Marker Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Marker Therapeutics$3.55M5.94-$12.16M-$0.61N/A
XBiotechN/AN/A-$45.54M-$1.32N/A

Marker Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

In the previous week, XBiotech had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for Marker Therapeutics. XBiotech's average media sentiment score of 1.16 beat Marker Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media.

Company Overall Sentiment
Marker Therapeutics Neutral
XBiotech Positive

XBiotech has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. XBiotech's return on equity of -26.10% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Marker Therapeutics-343.03% -73.29% -59.70%
XBiotech N/A -26.10%-25.06%

Summary

XBiotech beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRKR vs. The Competition

Export
MetricMarker TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$21.10M$3.54B$6.80B$13.01B
Dividend YieldN/A3.79%2.60%10.03%
P/E Ratio-2.087.36279.9825.51
Price / Sales5.941,272.68649.35116.02
Price / CashN/A44.8028.6434.82
Price / Book1.2517.1811.156.35
Net Income-$12.16M-$12.52M$3.48B$347.60M
7 Day Performance7.29%2.48%2.51%3.14%
1 Month Performance-13.88%-5.41%-2.78%-2.08%
1 Year Performance2.10%51.14%64.32%21.27%

Marker Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MRKR
Marker Therapeutics
1.8205 of 5 stars		$1.25
+2.5%		$10.00
+700.0%		-9.6%$20.85M$3.55MN/A60
THAR
Tharimmune
N/A$2.03
+4.6%		N/A+55.6%$76.59MN/AN/A2
GANX
Gain Therapeutics
1.9733 of 5 stars		$1.76
-5.6%		$7.50
+327.4%		+21.5%$74.90MN/AN/A20
FRMM
Forum Markets
3.5809 of 5 stars		$5.54
flat		$10.00
+80.5%		N/A$74.18M$6.55MN/A7
SPRO
Spero Therapeutics
1.0876 of 5 stars		$1.24
+4.7%		N/A-50.0%$71.51M$66.80M5.15150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
1 Stock to Own by July 31st
A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...
Chaikin Analytics | Sponsoredtc pixel
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Nvidia's CEO says this small device is critical for AI growth
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...
Brownstone Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel